Moderna is strengthening its commercial leadership and operational structure as it prepares for a series of anticipated vaccine launches over the next several years. The company expects potential introductions of its mRNA-based seasonal flu vaccine, combined flu/COVID-19 vaccine, and norovirus vaccine between 2027 and 2028. As part of this effort, Moderna has appointed Esther Banque, a former executive at Novartis, Bristol Myers Squibb, and Zoetis, as chief commercial officer. At the same time, company president Stephen Hoge has been given broader responsibilities across the organization. This Moderna Commercial Expansion comes as the company positions itself for a larger commercial footprint beyond its existing respiratory vaccine business.
The leadership changes were announced alongside the publication of an FDA briefing document concerning Moderna’s seasonal flu vaccine, mFlusiva, previously known as mRNA-1010. While the document highlighted certain limitations in the efficacy data submitted by the company, the overall assessment was supportive and suggested a favorable outcome ahead of the FDA advisory committee meeting. The development follows earlier regulatory uncertainty when the FDA initially declined to accept Moderna’s marketing application for mFlusiva before later reconsidering after discussions regarding a revised submission. The situation had drawn attention following public disagreements between Moderna and then FDA Commissioner Marty Makary, who had expressed criticism of mRNA vaccines and has since left the agency.
If approved, mFlusiva would join a growing pipeline that includes mRNA-1083, the combined flu/COVID vaccine already authorized in Europe under the mCombriax brand name, and the norovirus candidate mRNA-1403, currently being evaluated in the phase 3 NOVA 301 study with results expected next year. Under the new structure, Hoge will oversee operational and cross-functional leadership spanning research and development, manufacturing, and commercial activities. Banque will focus on expanding Moderna’s commercial capabilities globally and supporting growth in new markets.
Moderna currently markets COVID-19 vaccines Spikevax and mNEXSPIKE, which generated most of the company’s $389 million in first-quarter revenue, along with RSV vaccine mResvia. Chief executive Stéphane Bancel said the appointments are important as the company moves toward establishing three commercial franchises across vaccines, cancer, and rare diseases. Its oncology portfolio is led by MSD-partnered neoantigen therapy intismeran autogene for melanoma and non-small cell lung cancer (NSCLC), which remains in late-stage clinical development. In rare diseases, mRNA-3927 for propionic acidaemia (PA) is progressing through phase 1/2 testing. The latest Moderna Commercial Expansion reflects preparations for supporting these future product opportunities across multiple therapeutic areas.
